SCHEDULE 13G/A: JPMorgan Chase & Co. Amends Passive Stake in Alterity Therapeutics, Reports 4.0% Ownership

JPMorgan Chase & Co. has filed an Amendment No. 1 to its Schedule 13G, disclosing a 4.0% passive beneficial ownership stake in Alterity Therapeutics Limited as of April 30, 2025.

Summary

• JPMorgan Chase & Co. filed an Amendment No. 1 to Schedule 13G concerning its beneficial ownership in Alterity Therapeutics Limited.
• As of April 30, 2025, JPMorgan Chase & Co. beneficially owns 366,034,937 American Depositary Shares (ADS) of Alterity Therapeutics Limited.
• This ownership represents 4.0% of the class of American Depositary Shares, with each ADS representing 600 Ordinary Shares.
• JPMorgan Chase & Co. holds sole voting power and sole dispositive power over all 366,034,937 shares.
• The filing explicitly states that the securities are held in the ordinary course of business and were not acquired or held for the purpose of changing or influencing the control of the issuer.
• The filing was made by JPMorgan Chase & Co. as a parent holding company, identifying J.P. Morgan Securities Australia Limited and J.P. Morgan Securities PLC as relevant subsidiaries.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing (Schedule 13G) disclosing a passive ownership stake. It contains factual information without expressing positive or negative sentiment regarding the issuer's performance or outlook.

Positives

• The filing confirms a significant, albeit passive, investment by a major financial institution, JPMorgan Chase & Co., in Alterity Therapeutics Limited.
• The explicit statement that the holding is for ordinary course of business and not for control purposes provides clarity and indicates stability regarding the investor's intent.

Industry Context

This Schedule 13G filing indicates a passive investment by a major financial institution, JPMorgan Chase & Co., in Alterity Therapeutics Limited, a company likely operating in the biotechnology or pharmaceutical sector given its name. Such filings are routine disclosures for institutional investors holding less than 5% of a company's shares without intent to influence control, reflecting standard portfolio management activities rather than a strategic industry move.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional holder's passive stake, confirming no intent to influence control.
• Company Management: Confirms a large institutional investor holds a passive stake, not seeking to influence corporate governance or strategic direction.

Key Dates

Keywords

Alterity Therapeutics Limited, JPMorgan Chase & Co., Schedule 13G, Beneficial Ownership, American Depositary Shares, ADS, Passive Investment, SEC Filing, Biotechnology, Pharmaceuticals